SIGA Technologies Posts Q2 2024 Earnings, Maintains Strong Growth Amid Global Health Focus
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
SIGA Technologies, Inc. (NASDAQ: SIGA) reported solid financial results for Q2 2024. The company posted revenue of $21.81 million, largely driven by sales of its flagship product, TPOXX®, an antiviral medication used for smallpox and mpox (monkeypox). Earnings per share (EPS) came in at $0.03, exceeding analyst expectations.
Financial and Market Performance
• Revenue: $21.81 million, showing steady product sales.
• EPS: $0.03, beating forecasts.
• Stock Performance: The stock is trading around $10.13, up significantly year-to-date, with a strong P/E ratio of 9.49 .
Future Outlook
Analysts forecast earnings growth of 23.76% over the next year, with EPS expected to rise to $1.25 in 2025. SIGA’s focus on infectious disease treatments and government contracts positions it well for continued growth.
NOT TRADING ADVICE. ALWAYS DO YOUR OWN RESEARCH.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.